Seeyond Bio Rad Laboratories, Inc. Transaction History

Seeyond

$1.03 Billion
Q4 2022

A detailed history of Seeyond transactions in Bio Rad Laboratories, Inc. stock. As of the latest transaction made, Seeyond holds 3,546 shares of BIO stock, worth $1.15 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares

3,546

Previous 3,919 9.52%

Holding current value

$1.15 Million

Previous $1.63 Million 8.75%

% of portfolio

0.14%

Previous 0.2%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$351.71 - $456.01 $131,187 - $170,091	-373 Reduced 9.52%	3,546 $1.49 Million
Q3 2022 Nov 14, 2022	SELL	$412.59 - $563.26 $86,231 - $117,721	-209 Reduced 5.06%	3,919 $1.63 Million
Q2 2022 Aug 12, 2022	SELL	$463.67 - $597.16 $38,020 - $48,967	-82 Reduced 1.95%	4,128 $2.04 Million
Q1 2022 May 13, 2022	BUY	$524.57 - $735.42 $380,313 - $533,179	725 Added 20.8%	4,210 $2.37 Million
Q3 2021 Nov 12, 2021	SELL	$657.71 - $825.77 $482,759 - $606,115	-734 Reduced 17.4%	3,485 $2.6 Million
Q2 2021 Aug 13, 2021	BUY	$576.64 - $649.04 $10,956 - $12,331	19 Added 0.45%	4,219 $2.72 Million
Q4 2020 Feb 12, 2021	SELL	$510.68 - $643.45 $352,879 - $444,623	-691 Reduced 14.13%	4,200 $2.45 Million
Q3 2020 Nov 12, 2020	SELL	$454.43 - $535.6 $173,137 - $204,063	-381 Reduced 7.23%	4,891 $2.52 Million
Q2 2020 Aug 13, 2020	BUY	$334.87 - $493.06 $1.03 Million - $1.52 Million	3,087 Added 141.28%	5,272 $2.38 Million
Q1 2020 May 14, 2020	SELL	$320.01 - $409.07 $5,440 - $6,954	-17 Reduced 0.77%	2,185 $845,000
Q4 2019 Feb 14, 2020	BUY	$319.73 - $374.2 $704,045 - $823,988	2,202 New	2,202 $815,000

Others Institutions Holding BIO

# of Institutions

457

Shares Held

18.2M

Call Options Held

19.5K

Put Options Held

13.9K

View Full List

About BIO-RAD LABORATORIES, INC.

Ticker BIO
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 24,633,900
Market Cap $8.02B
Description
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, an...

More about BIO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Seeyond, based on Form 13F filings with the SEC.

News

Stay updated on Seeyond with notifications on news.

Account